• DOI:10.1016/S0304-3959(98)00019-0
Corpus ID: 30963675

Nimodipine-enhanced opiate analgesia in cancer patients requiring morphine dose escalation: a double-blind, placebo-controlled study

@article{Santilln1998NimodipineenhancedOA,
  title={Nimodipine-enhanced opiate analgesia in cancer patients requiring morphine dose escalation: a double-blind, placebo-controlled study},
  author={R. Santill{\'a}n and M. A. Hurl{\'e} and J. Armijo and R. D. L. Mozos and J. Fl{\'o}rez},
  journal={Pain},
  year={1998},
  volume={76},
  pages={17-26}
}

R. Santillán, M. A. Hurlé, +2 authors J. Flórez

Published 1998

Medicine

Pain

&NA; The ability of nimodipine, a dihydropyridine calcium antagonist, to reduce the daily dose of oral morphine in cancer patients who had developed dose escalation, was tested in 54 patients under randomized, double‐blind, placebo‐controlled conditions. We selected patients that required at least two successive increments of morphine to maintain pain relief. A possible pharmacokinetic interaction between nimodipine and morphine was also studied in 14 patients by assaying steady‐state serum… CONTINUE READING

View on Wolters Kluwer

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed